The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg

Zinger Key Points
  • FDA decisions were bad news for Amryt Pharma and Gilead Sciences, Inc. which failed to get their investigational drugs across the finish line.
  • SAB Biotherapeutics shares came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company's SAB-185 in COVID-19 patients.

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF IBB retreated in four out of five sessions of the week.

Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off.

NuCana plc. NCNA was among the worst decliners of the week, with the stock reacting to the stalling of the company's Phase 3 biliary tract cancer study.

SAB Biotherapeutics, Inc. SABS shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company's SAB-185 in COVID-19 patients. Celayad Oncology SA CYAD shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study.

FDA decisions scheduled for the week were mixed, with Amryt Pharma plc AMYT and Gilead Sciences, Inc. GILD failing to get their investigational drugs across the finish line. On the other hand, Legend Biotech Corporation LEGN and CTI BioPharma Corp. CTIC received approvals for their treatments for multiple myeloma and myelofibrosis, respectively.

Here are the key catalysts that can impact trading in biopharma stocks in the unfolding week:


Cowen 42nd Annual Health Care Conference (virtual): March 7-9


The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.


Eagle Pharmaceuticals, Inc. EGRX (before the market open)
DURECT Corporation DRRX (after the close)


Neuronetics, Inc. STIM (before the market open)
InspireMD, Inc. NSPR (before the market open)
Matinas BioPharma Holdings, Inc. MTNB (before the market open)
Harvard Bioscience, Inc. HBIO (before the market open)
Aquestive Therapeutics, Inc. AQST (after the close)
Accelerate Diagnostics, Inc. AXDX (after the close)
Anika Therapeutics, Inc. ANIK (after the close)
Cumberland Pharmaceuticals Inc. CPIX (after the close)
Evoke Pharma, Inc. EVOK (after the close)

Related Link: Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma


Selecta Biosciences, Inc. SELB (before the market open)
Assertio Holdings, Inc. ASRT (before the market open)
Acorda Therapeutics, Inc. ACOR (after the close)
Histogen Inc. HSTO (after the close)
Mirum Pharmaceuticals, Inc. MIRM (after the close)


Tecogen Inc. TGEN (before the market open)
TherapeuticsMD, Inc. TXMD (before the market open)
Lineage Cell Therapeutics, Inc. LCTX (before the market open)
Genocea Biosciences, Inc. GNCA (before the market open)
BioXcel Therapeutics, Inc. BTAI (before the market open)
Autolus Therapeutics plc AUTL (before the market open)
Amphastar Pharmaceuticals, Inc. AMPH (after the close)
Achieve Life Sciences, Inc. ACHV (after the close)
Clearside Biomedical, Inc. CLSD (after the close)
Eiger BioPharmaceuticals, Inc. EIGR (after the close)
Corvus Pharmaceuticals, Inc. CRVS (after the close)
OncoCyte Corporation OCX (after the close)
Geron Corporation GERN (after the close)
Lantern Pharma Inc. LTRN (after the close)
Zumiez Inc. ZUMZ (after the close)
Viridian Therapeutics, Inc. VRDN (after the close)
Neovasc Inc. NVCN (after the close)
Regulus Therapeutics Inc. RGLS (after the close)
Lumos Pharma, Inc. LUMO (after the close)
Salarius Pharmaceuticals, Inc. SLRX (after the close)


PLx Pharma Inc. PLXP (before the market open)


IPO Quiet Period Expiry

TC Biopharm (Holdings) Plc TCBP

Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates

Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksSmall CapTop StoriesGeneral